Pieris Pharmaceuticals, Inc. PIRS · Stock Open Pieris Pharmaceuticals, Inc. in new tab
Pieris Pharmaceuticals, Inc. Analysis (PIRS)
Is Pieris Pharmaceuticals, Inc. a good investment? Pieris Pharmaceuticals, Inc. (PIRS) is currently trading at 13.60 USD.
Investor FAQ
Does Pieris Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Pieris Pharmaceuticals, Inc.?
Pieris Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
Company Profile
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| April 23, 2024 | 1:100 |
Community Discussion